145 related articles for article (PubMed ID: 10739697)
1. Rare activation of the TCF/beta-catenin pathway in ovarian cancer.
Furlong MT; Morin PJ
Gynecol Oncol; 2000 Apr; 77(1):97-104. PubMed ID: 10739697
[TBL] [Abstract][Full Text] [Related]
2. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas.
Wu R; Zhai Y; Fearon ER; Cho KR
Cancer Res; 2001 Nov; 61(22):8247-55. PubMed ID: 11719457
[TBL] [Abstract][Full Text] [Related]
3. Beta- and gamma-catenin mutations, but not E-cadherin inactivation, underlie T-cell factor/lymphoid enhancer factor transcriptional deregulation in gastric and pancreatic cancer.
Caca K; Kolligs FT; Ji X; Hayes M; Qian J; Yahanda A; Rimm DL; Costa J; Fearon ER
Cell Growth Differ; 1999 Jun; 10(6):369-76. PubMed ID: 10392898
[TBL] [Abstract][Full Text] [Related]
4. Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis.
Mulholland DJ; Read JT; Rennie PS; Cox ME; Nelson CC
Oncogene; 2003 Aug; 22(36):5602-13. PubMed ID: 12944908
[TBL] [Abstract][Full Text] [Related]
5. Constitutive activation of Wnt/beta-catenin signaling pathway in migration-active melanoma cells: role of LEF-1 in melanoma with increased metastatic potential.
Murakami T; Toda S; Fujimoto M; Ohtsuki M; Byers HR; Etoh T; Nakagawa H
Biochem Biophys Res Commun; 2001 Oct; 288(1):8-15. PubMed ID: 11594745
[TBL] [Abstract][Full Text] [Related]
6. Mutant E-cadherin breast cancer cells do not display constitutive Wnt signaling.
van de Wetering M; Barker N; Harkes IC; van der Heyden M; Dijk NJ; Hollestelle A; Klijn JG; Clevers H; Schutte M
Cancer Res; 2001 Jan; 61(1):278-84. PubMed ID: 11196175
[TBL] [Abstract][Full Text] [Related]
7. Cross-talk between Rac1 GTPase and dysregulated Wnt signaling pathway leads to cellular redistribution of beta-catenin and TCF/LEF-mediated transcriptional activation.
Esufali S; Bapat B
Oncogene; 2004 Oct; 23(50):8260-71. PubMed ID: 15377999
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of monocyte chemotactic protein-3 by activated beta-catenin.
Fujita M; Furukawa Y; Nagasawa Y; Ogawa M; Nakamura Y
Cancer Res; 2000 Dec; 60(23):6683-7. PubMed ID: 11118053
[TBL] [Abstract][Full Text] [Related]
9. Tcf binding sequence and position determines beta-catenin and Lef-1 responsiveness of MMP-7 promoters.
Gustavson MD; Crawford HC; Fingleton B; Matrisian LM
Mol Carcinog; 2004 Nov; 41(3):125-39. PubMed ID: 15457508
[TBL] [Abstract][Full Text] [Related]
10. Selective targeting to the hyperactive beta-catenin/T-cell factor pathway in colon cancer cells.
Chen RH; McCormick F
Cancer Res; 2001 Jun; 61(11):4445-9. PubMed ID: 11389074
[TBL] [Abstract][Full Text] [Related]
11. Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas.
Schwartz DR; Wu R; Kardia SL; Levin AM; Huang CC; Shedden KA; Kuick R; Misek DE; Hanash SM; Taylor JM; Reed H; Hendrix N; Zhai Y; Fearon ER; Cho KR
Cancer Res; 2003 Jun; 63(11):2913-22. PubMed ID: 12782598
[TBL] [Abstract][Full Text] [Related]
12. A comparative evaluation of beta-catenin and plakoglobin signaling activity.
Williams BO; Barish GD; Klymkowsky MW; Varmus HE
Oncogene; 2000 Nov; 19(50):5720-8. PubMed ID: 11126358
[TBL] [Abstract][Full Text] [Related]
13. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors.
Crawford HC; Fingleton BM; Rudolph-Owen LA; Goss KJ; Rubinfeld B; Polakis P; Matrisian LM
Oncogene; 1999 May; 18(18):2883-91. PubMed ID: 10362259
[TBL] [Abstract][Full Text] [Related]
14. Plakoglobin (gamma-catenin) has TCF/LEF family-dependent transcriptional activity in beta-catenin-deficient cell line.
Maeda O; Usami N; Kondo M; Takahashi M; Goto H; Shimokata K; Kusugami K; Sekido Y
Oncogene; 2004 Jan; 23(4):964-72. PubMed ID: 14661054
[TBL] [Abstract][Full Text] [Related]
15. Lymphoid enhancer factor 1 makes cells resistant to transforming growth factor beta-induced repression of c-myc.
Sasaki T; Suzuki H; Yagi K; Furuhashi M; Yao R; Susa S; Noda T; Arai Y; Miyazono K; Kato M
Cancer Res; 2003 Feb; 63(4):801-6. PubMed ID: 12591729
[TBL] [Abstract][Full Text] [Related]
16. Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells.
de la Taille A; Rubin MA; Chen MW; Vacherot F; de Medina SG; Burchardt M; Buttyan R; Chopin D
Clin Cancer Res; 2003 May; 9(5):1801-7. PubMed ID: 12738737
[TBL] [Abstract][Full Text] [Related]
17. Transactivation of vimentin by beta-catenin in human breast cancer cells.
Gilles C; Polette M; Mestdagt M; Nawrocki-Raby B; Ruggeri P; Birembaut P; Foidart JM
Cancer Res; 2003 May; 63(10):2658-64. PubMed ID: 12750294
[TBL] [Abstract][Full Text] [Related]
18. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer.
Sparks AB; Morin PJ; Vogelstein B; Kinzler KW
Cancer Res; 1998 Mar; 58(6):1130-4. PubMed ID: 9515795
[TBL] [Abstract][Full Text] [Related]
19. Activation of Wnt/beta-catenin/Tcf signaling in mouse skin carcinogenesis.
Bhatia N; Spiegelman VS
Mol Carcinog; 2005 Apr; 42(4):213-21. PubMed ID: 15765534
[TBL] [Abstract][Full Text] [Related]
20. Frequent alterations of the beta-catenin and TCF-4 genes, but not of the APC gene, in colon cancers with high-frequency microsatellite instability.
Fukushima H; Yamamoto H; Itoh F; Horiuchi S; Min Y; Iku S; Imai K
J Exp Clin Cancer Res; 2001 Dec; 20(4):553-9. PubMed ID: 11876551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
